Carolyn Beaver - 23 Jun 2026 Form 4 Insider Report for MEDICINOVA INC (MNOV)

Reporting relationship: Director
Issuer ticker: MNOV
Reported as of: 23 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 25 Jun 2026, 16:35:05 UTC
Prior SEC filing: 22 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Yuichi Iwaki, attorney-in-fact

Key filing fact

Carolyn Beaver filed Form 4 for MEDICINOVA INC (MNOV) on 25 Jun 2026.

Key facts

This page summarizes Carolyn Beaver's Form 4 filing for MEDICINOVA INC (MNOV).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 25 Jun 2026, 16:35.

Change

Previous filing in this sequence was filed on 22 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001335581 Primary reporting owner

BEAVER CAROLYN

Relationship: Director
Address: C/O MEDICINOVA, INC., 4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA
Signature: /s/ Yuichi Iwaki, attorney-in-fact
Signature date: 25 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MNOV transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +44,500
Change %
Price: $0.000000^*
Shares after: 44,500
Date: 23 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 44,500
Exercise price: $1.36
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests in four equal installments on September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027, subject to continued service with the Company.